What "Ganoderma lucidum" Actually Means on a Reishi CoA
Almost no commercial reishi is Ganoderma lucidum. Three binomials, an unresolved nomenclature dispute, a measured chemical difference, and what to specify instead.
Executive Summary
If your reishi specification says Ganoderma lucidum, it is probably naming an organism that is not in your drum.
That is not an accusation of fraud. It is the residue of a taxonomic error that ran for over a century, and it is still propagating through spec sheets, CoAs and ingredient labels today. When researchers sequenced commercial reishi products, G. lucidum in the strict sense was not detected in a single one of nineteen manufactured products tested[4]. A separate study of seven supplements from seven independent suppliers found G. lingzhi DNA in all seven[5].
This matters commercially for one specific reason: the two organisms are not chemically equivalent. Extracts of G. lingzhi produce significantly more triterpenic acids than extracts of G. lucidum sensu stricto[6]. So the name on the document matters. It can track the fraction most premium reishi is sold on.
1. What Went Wrong, Briefly
Ganoderma was erected by Karsten in 1881 on a type specimen — G. lucidum — from England[3]. The East Asian cultivated Lingzhi was assigned to that European name and stayed there for roughly a century.
Morphological work by Pegler and Yao first suggested the Chinese cultivated material was not conspecific with the European species, and molecular phylogenetics subsequently confirmed it: Asian collections separate from European G. lucidum into distinct clades[3]. G. lucidum sensu stricto has a limited native distribution in Europe and parts of China; it is closely related to North American G. oregonense and G. tsugae, not to the cultivated Asian material[4][5].
So "G. lucidum" on a reishi label is best read as a legacy trade convention rather than a species determination.
2. Three Binomials, and Why the Dispute Is Still Open
Where the industry gets uncomfortable is that mycology has not fully settled on the replacement name. Two research groups reached different conclusions within months of each other in 2012, and the argument is about type specimens rather than about biology.
| Name | Proposed by | Argument | Status |
|---|---|---|---|
| Ganoderma lucidum (Curtis) P. Karst. | Karsten, 1881 | Genus type, from England | Real species — but not the cultivated Asian one |
| Ganoderma sichuanense J.D. Zhao & X.Q. Zhang | Zhao & Zhang, 1983; applied to Lingzhi by Wang et al. 2012 | Earlier published name; epitype designated to fix its application | Supported as correct by Du et al. 2023[3] |
| Ganoderma lingzhi Sheng H. Wu, Y. Cao & Y.C. Dai | Cao et al., 2012 | Described as new; holotype of G. sichuanense argued not to match Lingzhi | Supported as correct by Dai et al. 2017[2]; widely used in literature |
The 2012 description of G. lingzhi distinguished it from G. lucidum on morphological characters including the pore surface and the dissepiments[1].
The counter-argument from Dai and colleagues is procedural: they hold that the holotype of G. sichuanense does not carry the typical morphological characteristics of Lingzhi, that the designated epitype is not conspecific with that holotype morphologically, phylogenetically or ecologically, and that the epitypification therefore conflicts with the Code and should be rejected[2].
Du et al. went back to the physical holotype (HMAS 42798) in 2023 and re-examined the single contested ITS sequence. Using six specific primers plus one universal primer, directed and nested PCR, they recovered nine ITS sequences from the holotype, and assembled the ITS of the first cultivated Lingzhi specimen (HMAS 25103) by genome sequencing. Their conclusion: the correct name for the widely cultivated Chinese Ganoderma is G. sichuanense, and G. lingzhi is a later synonym[3].
They also report a finding that helps explain why the question stayed open. The holotype shows ITS heterogeneity across all three parts of the region (ITS1, 5.8S and ITS2) — the first such report for this taxon — which they suggest "might be the nature of the species"[3]. Attempts to amplify any other locus from the holotype failed because the DNA was too degraded, so the resolution rests on a single-locus argument. The authors say so themselves: for complex groups in Ganoderma, multigene analyses are essential[3].
Both names refer to the same organism — the cultivated East Asian Lingzhi. The dispute is nomenclatural, not biological, and it is not resolved. Specifications should not be written as though one name has been settled on. Naming the clade and attaching a sequence is more durable than betting on a binomial.
3. What Sequencing Found in Actual Products
The market data is more useful to a buyer than the nomenclature is.
Loyd et al. analysed 20 manufactured reishi products (capsules, powders, tablets, coffee, tea) and 17 "grow your own" kits, all labelled G. lucidum[4].
| Finding | Result |
|---|---|
| GYO kits correctly labelled | 2 of 17 |
| GYO kits mislabelled | 15 — actually G. lingzhi (7), G. sessile (4), G. resinaceum s.l. (3), G. curtisii (1) |
| Manufactured products containing G. lucidum s.str. | 0 of 19 successfully sequenced |
| Manufactured products containing more than one Ganoderma species | 16 of 19 |
| Products dominated by G. lingzhi with negligible other reads | 14 of 19 (74%) |
Two things stand out. First, the GYO kits contained North American and European species — G. sessile, G. curtisii, G. resinaceum — that are not the traded article at all. Second, and more relevant to bulk buyers, 16 of 19 manufactured products contained multiple Ganoderma species by meta-barcoding, though in most cases the non-G. lingzhi reads were under 5% of the total[4].
The Gunnels et al. study is the cleaner design for supplier-level inference: seven samples from seven distinct suppliers rather than multiple retail SKUs from the same source. All seven were sold as G. lucidum; all seven were G. lingzhi. Their read of the mechanism is worth quoting in substance — misidentification is applied early in the chain and inherited downstream by everyone else[5].
On the chemistry side, Wu et al. profiled 19 G. lucidum dietary supplements bought in the US using HPTLC, GC-MS, saccharide mapping and HPSEC-MALLS-RID, and found only 5 of 19 (26.3%) consistent with their label claims on triterpene and polysaccharide content[7]. That is a composition problem rather than a species problem, but it points at the same underlying condition: reishi is a category where the document and the material have historically drifted apart.
4. Why the Name Tracks a Real Chemical Difference
If G. lucidum and G. lingzhi were chemically interchangeable, this would only be a naming problem. The available comparison says they are not.
Hennicke et al. compared two commercially sold strains — M9720 and M9724, both sold as "G. lucidum" by the same European supplier. Morphology assigned M9720 to G. lucidum s.str. and M9724 to G. lingzhi; ITS and beta-tubulin sequences independently grouped M9720 with European G. lucidum and M9724 with East Asian G. lingzhi. UPLC-ESIMS profiling of ethanol extracts of the ground basidiocarps found substantially fewer triterpenic acids in the G. lucidum s.str. extract[6].
In commercial terms: two strains, one supplier, one label, and a measurable gap in the fraction that dual-extract reishi is priced on.
One limitation applies before anyone writes this into a contract: that comparison is two strains, not a population survey, and it does not license a general "G. lingzhi assays higher" clause. It establishes that species identity is a plausible source of triterpene variance between lots — which is a reason to control identity, not a substitute for measuring the triterpenes.
5. What to Specify
Ask what the identity determination actually was. Macroscopic and microscopic evaluation confirms the material is a laccate Ganoderma. It does not separate G. lingzhi from G. lucidum s.str., and it cannot be done on a powder at all — Gunnels et al. note their powdered samples were macroscopically unidentifiable as mushroom[5]. If the CoA says "identity: organoleptic / microscopic," that is a genus-level answer to a species-level question.
Ask for the ITS sequence, not just an identity pass/fail. ITS works well for this genus: in the Gunnels study, average genetic identity between store-bought samples and the closest GenBank accession was 99.8%[5]. A supplier who can hand you an ITS read and an accession number has answered the question in a form you can independently verify. Where finer provenance matters, a second faster- evolving locus such as tef1α is the standard addition[4][5].
Accept either binomial, and say so in writing. Given the unresolved dispute, a specification that hard-codes one name will eventually conflict with a supplier's paperwork for no good reason. Language along the lines of "Ganoderma lingzhi (=G. sichuanense), the cultivated East Asian Lingzhi clade; not G. lucidum sensu stricto" survives whichever way the nomenclature lands. Note that the widely used industry reference Herbs of Commerce lists G. japonicum, G. lucidum and G. tsugae under "reishi" and omits the cultivated species entirely, so upstream reference works will not do this for you[5].
Remember that our CoA does not discharge your obligation. US dietary supplement cGMP requires identity verification on 100% of incoming lots of each dietary ingredient, and a supplier's Certificate of Analysis does not satisfy that requirement — at least one appropriate test or examination must be performed by the manufacturer, with exemption available only by petition to FDA[8][5]. Whatever we send you, someone on your side has to run an identity test. Making that test easy is part of what a supplier is for.
Treat multi-species reads as a process question. Sixteen of nineteen products carrying more than one Ganoderma species is not principally an adulteration finding — low-level reads can come from shared cultivation facilities, spawn handling or sequencing artefacts. It is a reason to ask about substrate, spawn provenance and facility segregation rather than to assume intent[4].
Where This Leaves Our Own Reishi
Our reishi is cultivated fruiting-body material grown on hardwood substrate under controlled conditions. Parts of our product documentation still use the conventional binomial Ganoderma lucidum, as most of the trade does. By the argument above, that is the legacy name rather than the precise one.
If you need species identity fixed at the sequence level for a regulated market or an audit file, raise it in the specification discussion and we will tell you what we can evidence and what we cannot.
See the reishi specification →
Request identity documentation and batch CoAs →
References
[1] Cao et al. (2012). Species clarification of the prize medicinal Ganoderma mushroom 'Lingzhi'. Fungal Diversity 56:49-62. Retrieved from https://link.springer.com/article/10.1007/s13225-012-0178-5
[2] Dai et al. (2017). Ganoderma lingzhi (Polyporales, Basidiomycota): the scientific binomial for the widely cultivated medicinal fungus Lingzhi. Mycological Progress 16:1051-1055. Retrieved from https://link.springer.com/article/10.1007/s11557-017-1347-4
[3] Du et al. (2023). Re-Examination of the Holotype of Ganoderma sichuanense (Ganodermataceae, Polyporales) and a Clarification of the Identity of Chinese Cultivated Lingzhi. Journal of Fungi 9(3):323. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10051598/
[4] Loyd et al. (2018). Identifying the 'Mushroom of Immortality': Assessing the Ganoderma Species Composition in Commercial Reishi Products. Frontiers in Microbiology 9:1557. Retrieved from https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2018.01557/full
[5] Gunnels et al. (2020). The ITS region provides a reliable DNA barcode for identifying reishi/lingzhi (Ganoderma) from herbal supplements. PLoS ONE 15(11):e0236774. Retrieved from https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0236774
[6] Hennicke et al. (2016). Distinguishing commercially grown Ganoderma lucidum from Ganoderma lingzhi from Europe and East Asia on the basis of morphology, molecular phylogeny, and triterpenic acid profiles. Phytochemistry 127:29-37. Retrieved from https://www.sciencedirect.com/science/article/pii/S0031942216300413
[7] Wu et al. (2017). Evaluation on quality consistency of Ganoderma lucidum dietary supplements collected in the United States. Scientific Reports 7:7792. Retrieved from https://www.nature.com/articles/s41598-017-06336-3
[8] US FDA (2026). 21 CFR 111.75 - What must you do to determine whether specifications are met?. Electronic Code of Federal Regulations. Retrieved from https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-111/subpart-E/section-111.75
More from Viridia
Keep exploring
Wild-Harvested Blue-Green Algae Is Often Not Spirulina
The main wild-harvested blue-green algae product, from Upper Klamath Lake, is a different genus, harvested from a lake where a microcystin producer blooms. Cultivated Limnospira has no genetic capacity to make microcystins. Any microcystin in a spirulina lot comes from a contaminant, and 'cultivated' is not a specification on its own.
Phycocyanin's Antioxidant Mechanism: Where the Biliverdin Reductase Story Is Established, and Where It Stops
The phycocyanobilin-to-phycocyanorubin pathway is real enzymology. The leap from that pathway to an antioxidant claim on a finished product crosses four steps, and only the first is settled. A dose-arithmetic check on what the rodent data would actually require.
Erinacines, Hericenones, and Which Lion's Mane the Trials Actually Used
The two headline Lion's Mane compound families sit in different tissues. Hericenones failed a human-cell NGF assay. What a CoA should carry.